# CJC-1295 Dosage in the Research: Doses, Route, and Half-Life

> CJC-1295 dosage in the literature: human PK studies used 30, 60, or 90 µg/kg subcutaneous; the DAC half-life is 5.8-8.1 days. Research context, not a recommendation.

What was administered, to which species, by which route — reported as study context for a compound with no approved human dose.

## CJC-1295 dosage in the research literature

CJC-1295 dosage in the published record means study doses, not a protocol. Human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 µg/kg in healthy adults [1] [3]. The GHRH-knockout-mouse growth study used 2 µg per dose at 24-, 48-, or 72-hour intervals, and the once-daily 24-hour schedule was the one that normalized growth [4].

Those doses were chosen to characterize pharmacokinetics, not to define a use regimen. In the human studies the point was to read the dose-response of GH and IGF-1 over days — to learn that 30 µg/kg and 60 µg/kg produce different, dose-dependent multi-day elevations [1] — not to recommend a microgram target. The doses are best read as the inputs to a kinetic experiment.

Community and clinic 'protocols' for the no-DAC Modified GRF 1-29 and for CJC-1295/ipamorelin commonly cite 100-to-300 µg fixed doses, but these are not derived from controlled human trials. They are reported here as what circulates, not as evidence. The only doses with a peer-reviewed pharmacokinetic basis are the 30-to-90 µg/kg single-dose human studies [1] [3] and the 2 µg mouse study [4] — and none of those was conducted to establish a human dose, because CJC-1295 has no approved human indication.

## Route and the half-life that shapes a schedule

Every characterized CJC-1295 study used the subcutaneous route; as a peptide, its oral bioavailability is negligible [1]. Early GRF(1-29) pharmacokinetic work also used the intravenous route, but subcutaneous injection is the route the human PK studies relied on [1] [3].

The half-life is what makes the DAC form's pharmacokinetics distinctive: 5.8 to 8.1 days in healthy adults, with IGF-1 elevated up to 28 days after multiple doses [1]. That is the basis for the once-daily schedule that normalized growth in GHRH-knockout mice [4]. The no-DAC Modified GRF 1-29 is short-acting by contrast, clearing in the minutes-to-hours range — the [half-life of the DAC variant](/cjc-1295-dac) and the no-DAC form differ by orders of magnitude, which is why the two forms imply completely different dosing cadences.

## Handling context

In research handling, CJC-1295 is a lyophilized peptide reconstituted with bacteriostatic water and refrigerated; the four substitutions confer DPP-IV and protease resistance, and DAC conjugation confers the multi-day duration [2]. This is laboratory handling context for a research chemical, not a use instruction. CJC-1295 is not approved for human use, the human evidence is limited to early pharmacokinetic studies, and most dosing figures online are not derived from controlled trials.

## How much CJC-1295 should I take?

There is no recommended human dose. Human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 µg/kg [1] [3]; these are study doses, not a human dosing recommendation, and CJC-1295 is not approved for human use. Any fixed-microgram 'protocol' online lacks a controlled-trial basis.

## How to reconstitute CJC-1295?

In research handling the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated [2]. This is described as laboratory handling context, not a use instruction for a compound that is not approved for human use.

## Where to inject CJC-1295?

Studies used the subcutaneous route; oral bioavailability is negligible [1]. This is the route the research used, not a use instruction — CJC-1295 has no approved human indication.

---

An inscribed codex of the CJC-1295 literature — the DAC and no-DAC record set in gold and read straight, with no clinic behind the archive and nothing here dispensed or sold.